INS and metabolic dysfunction-associated steatotic liver disease: In particular, lipids (triglycerides and/or cholesterol in Fatty Liver Index, SteatoTest, SHIP score, NAFLD ridge score and Dallas Steatosis Index) and glycemic parameters (glucose, hemoglobin A1c and/or insulin in the United States Fatty Liver Index, NAFLD liver fat score, SteatoTest, NAFLD ridge score and Dallas Steatosis Index) are affected by drug treatments.